Drug Transporter (DT) Information

General Information of DT
DT ID DTD0248
Gene Name SLC29A2
Protein Name Equilibrative nucleoside transporter 2
Gene ID
3177
UniProt ID
Q14542
TCDB ID
2.A.57.1.8
3D Structure

Modelled DT Structure

Method: homology modeling

Template PDB: 6OB6_A

Identity: 45.61%

Minimized Score: -1173.61 kcal/mol

Detail: Structure Info

Synonyms 36 kDa nucleolar protein HNP36; DER12; Delayed-early response protein 12; ENT2; Equilibrative NBMPR-insensitive nucleoside transporter; Equilibrative nitrobenzylmercaptopurine riboside-insensitive nucleoside transporter; HNP36; Hydrophobic nucleolar protein; Nucleoside transporter, ei-type; SLC29A2; Solute carrier family 29 member 2
DT Family Equilibrative Nucleoside Transporter (ENT) Family ;
Tissue Specificity Expressed in skeletal muscle, liver, lung,placenta, brain, heart, kidney and ovarian tissues.
Function This transporter mediates equilibrative transport of purine, pyrimidine nucleosides and the purine base hypoxanthine. Very less sensitive than SLC29A1 to inhibition by nitrobenzylthioinosine (NBMPR), dipyridamole, dilazep and draflazine.
Disease(s) Herpes simplex virus infection [ICD-11: 1F00]
Endogenous Substrate(s) Nucleosides
Variability Data of This Drug Transporter (DT)

Regulatory Variability Data of This DT (VARIDT 3.0)

(β) Post-translational Modification of This DT
Post-translational Modification (PTM)

(γ) Transcriptional Regulation of This DT
Transcriptional Regulation (TSR)

(δ) Epigenetic Regulation of This DT
Epigenetic Regulation (EGR)

(ε) Exogenous Modulation of This DT
Exogenous Modulation (EGM)

Structural Variability Data of This DT (VARIDT 2.0)

(β) Inter-species Structural Differences
Inter-species Structural Differences (ISD)

(δ) Xenobiotics-regulated Structural Variability
Xenobiotics-regulated Structural Variability (XSV)

General Variability Data of This DT (VARIDT 1.0)

(β) Disease-specific Protein Abundances of This DT
Disease-specific Protein Abundances of This DT (DPAD)

(γ) Species- and Tissue-specific DT Abundances
Species/Tissue-specific Protein Abundances of This DT (S/TPAD)
Molecular Transporting Profile of This DT

Full List of Drug(s) Transported by This DT

 Approved Drug

 Click to Show/Hide the Full List of Drug:            5 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Clofarabine
 Approved Drug Info Juvenile myelomonocytic leukemia 2A42 [1]
Cytarabine
 Approved Drug Info Acute myeloid leukemia 2A60 [2]
Entecavir
 Approved Drug Info Chronic hepatitis B infection 1E51.0 [3]
Mercaptopurine
 Approved Drug Info Acute lymphoblastic leukemia 2B33.0 [4]
Trifluridine
 Approved Drug Info Herpes simplex virus infection 1F00 [5]
References
1 Cytarabine-resistant leukemia cells are moderately sensitive to clofarabine in vitro. Anticancer Res. 2014 Apr;34(4):1657-62.
2 FLT3 is implicated in cytarabine transport by human equilibrative nucleoside transporter 1 in pediatric acute leukemia. Oncotarget. 2016 Aug 2;7(31):49786-49799.
3 Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos. 2017 Mar;45(3):269-278.
4 PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA2040)
5 Lonsurf, INN-trifluridine/tipiracil.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.